All systems operational
Good morning, Dr. Mehta
Your portfolio of 23 active trials is tracking 6.4% ahead of plan. The AI Workforce closed 41 tasks overnight and flagged 3 issues for your review.
23
Active trials
+3
8,412
Patients enrolled
+6.4% vs plan
412
Sites active
+12 this week
$184.2M
Budget burn YTD
-2.1% vs forecast
17
Reg submissions
4 due in 14d
2
Open safety signals
-1 vs last wk
Portfolio
Enrollment vs target
Cumulative patients across 23 active trials — tracking 6.4% ahead of plan.
+6.4%
Portfolio mix
Trials by phase
- Phase I4
- Phase II9
- Phase III7
- Phase IV3
Weekly burn ($M)
Trials
Active programs
| Trial | Phase | Status | Sites | Enrollment | Risk |
|---|---|---|---|---|---|
CDOS-201 Non-small cell lung cancer | Phase II | Enrolling | 42 | 286/320 | low |
CDOS-118 Atopic dermatitis | Phase III | Active | 86 | 612/600 | low |
CDOS-307 Type 2 diabetes | Phase III | At Risk | 64 | 412/540 | high |
CDOS-094 Multiple sclerosis | Phase II | Enrolling | 31 | 148/200 | med |
CDOS-412 Heart failure (HFpEF) | Phase I | Startup | 12 | 38/60 | low |
AI Insights
Updated 4 minutes ago
CDOS-307 enrollment lagging by 24%
AI recommends activating 8 additional sites in the Midwest and shifting $1.2M to recruitment campaigns.
Apply recommendation FDA Type-B meeting opportunity
Pre-IND meeting slot opens Aug 14 for CDOS-412. Drafting briefing book…
Open draft Site activation accelerated
12 sites cleared startup this week — 6 days ahead of plan. AI auto-routed contracts for signature.
View timeline AI Workforce
8 agents active · 41 tasks/24h
Live
Predictive forecast
FPI on CDOS-412 in 19 days
85% confidence based on site readiness, IRB cadence, and historical baselines.
Open forecast